Can blood work determine cancer
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Can Blood Work Determine Cancer?
Introduction to Blood-Based Cancer Detection
Blood tests have emerged as a promising tool for the early detection of cancer. These tests can identify molecular markers associated with cancer, offering a minimally invasive method to screen for multiple cancer types. Recent studies have explored various blood-based diagnostic methods, including the detection of circulating tumor DNA (ctDNA), protein biomarkers, and other blood components.
Multicancer Blood Tests and PET-CT Imaging
A significant study by Lennon et al. evaluated the feasibility of using a multicancer blood test combined with positron emission tomography-computed tomography (PET-CT) imaging to detect cancer in a large cohort of women with no prior history of cancer. The study found that the blood test detected 26 cancers of different types, and when combined with PET-CT, it led to the surgical removal of nine cancers. The specificity and positive predictive value (PPV) of the blood test alone were 98.9% and 19.4%, respectively, which increased to 99.6% and 28.3% when combined with PET-CT.
Full Blood Count (FBC) and Colorectal Cancer Detection
A systematic review and meta-analysis focused on the Full Blood Count (FBC) test, which includes 20 components, found that several components such as red blood cells, hemoglobin, mean corpuscular volume, red blood cell distribution width, white blood cell count, and platelets are associated with colorectal cancer diagnosis. Thirteen FBC-based prediction models were developed, showing varying degrees of accuracy with c-statistics ranging from 0.72 to 0.91.
Cell-Free DNA (cfDNA) and Tumor Origin Detection
Cell-free DNA (cfDNA) assays have shown promise in determining the tissue of origin (TOO) for various cancers. A meta-analysis of cfDNA-based tests reported an accuracy of 79% for predicting the primary site of cancers. The accuracy varied across cancer types, with colorectal cancers showing the highest accuracy and liver & bile duct cancers the lowest .
CancerSEEK: A Multi-Analyte Blood Test
The CancerSEEK test, which assesses circulating protein biomarkers and tumor-specific mutations in ctDNA, demonstrated the ability to detect eight common cancer types with sensitivities ranging from 69% to 98% and a specificity of 99%. This test was applied to patients with nonmetastatic cancers and showed a median detection rate of 70% across the eight cancer types.
Liquid Biopsy and Genetic Profiling
Liquid biopsies, which analyze ctDNA and circulating tumor cells (CTCs), offer a noninvasive method to monitor cancer genetics in real-time. These tests can provide insights into cancer evolution, invasion, and metastasis, and are useful for guiding precision cancer therapies. They can also track genomic changes over time, which is crucial for adjusting treatment strategies .
Emerging Technologies in Blood-Based Cancer Detection
Innovative approaches such as tumor-activatable minicircles, which use a tumor-specific promoter to drive the expression of a detectable reporter in the blood, have shown potential in distinguishing tumor-bearing from tumor-free subjects. This method could improve the accuracy of cancer detection and enable timely interventions.
Conclusion
Blood work, through various advanced diagnostic methods, can indeed play a crucial role in detecting cancer. Multicancer blood tests, FBC components, cfDNA assays, and liquid biopsies have all shown promise in identifying cancer at early stages and determining the tissue of origin. These advancements in blood-based cancer detection offer a minimally invasive, accurate, and potentially life-saving approach to cancer screening and monitoring. Further research and development are needed to enhance the accuracy, cost-effectiveness, and clinical utility of these tests.
Sources and full results
Most relevant research papers on this topic